THE ALGORITHM FOR THE TREATMENT OF PATIENTS WITH TREATMENT-RESISTANT HYPERTENSION AT THE OUTPATIENT STAGE
DOI:
https://doi.org/10.34287/MMT.1(56).2023.11Abstract
Every year in the world, arterial hypertension is the cause of death in about 9 million cases. Blood pressure control in patients has not yet reached the appropriate level, and the percentage of resistant arterial hypertension remains high. According to the definition of the American Heart Association, those patients whose condition requires taking four or more drugs to control blood pressure should be considered resistant to treatment. It should be understood that uncontrolled hypertension is not synonymous with RAH. The presence of RAH significantly increases the risk of cardiovascular complications, contributes to serious damage to target organs. Preliminary diagnosis of RAH definitely requires the exclusion of secondary hypertension, which is a rather heterogeneous group of diseases that is poorly recognized.
The goal of the work. To acquaint general practice - family medicine doctors with the algorithm of treatment of patients with resistant arterial hypertension at the ambulatory stage.
Treatment of patients with RAH should be carried out in stages, with increased therapy, using the most simplified scheme of taking drugs. Today, the combination of ACEI (perindopril), BCC (amlodipine) and diuretic (indapamide) is considered as the most optimal triple combination of antihypertensive drugs. Medicines containing three antihypertensive drugs in one tablet are offered precisely for RAH patients.
Conclusions. The implementation of the algorithm for the examination of patients with RAH, recommendations for changing their lifestyle and a step-by-step therapy plan allow improving the control of blood pressure. Treatment of patients with RAH should include optimization of dosages and the appointment of rational combinations of antihypertensive drugs in order to enhance synergistic effects. Optimization of pharmacotherapy by prescribing drugs with fixed combinations can improve control of drug administration. The fixed combination of amlodipine-indapamide-perindopril may have the important advantage of increasing treatment adherence due to the principle of "one pill per day".
References
Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol. 2019; 74(20): 2529-2532.
Gheorghe A, Griffiths U, Murphy A, et al. The economic burden of cardiovascular disease and hypertension in low-and middle-income countries: a systematic review. BMC public health. 2018; 18(1): 1-11.
elujko VY. Realyy lechenyja arteryal'noj gypertenzyy v Ukrayne: rezul'tatы kogortnogo yssledovanyja SYSTEMA-2. Ukrai'ns'kyj kardiologichnyj zhurnal. 2018; 1: 13-20..
Svishhenko JeP. Kliniko-demografichni harakterystyky pacijentiv z upershe vyjavlenoju arterial'noju gipertenzijeju: rezul'taty doslidzhennja START. Ukrai'ns'kyj kardiologichnyj zhurnal. 2017; 6: 14-23.
Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018; 72(5): e53-e90.
Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019; 73(5): e35-e66.
Williams B., Mancia G., Spiering W. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European heart journal. 2018; 39(33): 3021-3104.
Kim S, Park JJ, Shin MS, et al. Apparent treatment-resistant hypertension among ambulatory hypertensive patients: a cross-sectional study from 13 general hospitals. The Korean Journal of Internal Medicine. 2021; 36(4): 888-897.
Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125(13): 1635-1642.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH / ASPC / NMA / PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018; 71(19): e127-e248.
Denolle T, Chamontin B, Doll G, et al. Management of resistant hypertension: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. Journal of Human Hypertension. 2016; 30(11): 657-663.
Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends in cardiovascular medicine. 2020; 30(3): 160-164.
Acelajado MC, Hughes ZH, Oparil S, et al. Treatment of resistant and refractory hypertension. Circulation research. 2019; 124(7): 1061-1070.
Veglio F, Mulatero P. Resistant or refractory hypertension: it is not just the of number of drugs. Journal of Hypertension. 2021; 39(3): 589-591.
Estrada D, Sierra C, Soriano RM, et al. Grade of knowledge of hypertension in hypertensive patients. Enfermería Clínica (English Edition). 2020; 30(2): 99-107.
Hwang AY, Dietrich E, Pepine CJ, et al. Resistant hypertension: mechanisms and treatment. Current Hypertension Reports. 2017; 19(7): 1-11.
Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen?. European heart journal. 2014; 35(19): 1245-1254.
Haeusler KG, Huttner HB, Kuramatsu JB. Comment on 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2019; 40(25); 2092-2092.
Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Canadian Journal of Cardiology. 2020; 36(5): 596-624.
Hwang AY, Dave CV, Smith SM. Use of prescription medications that potentially interfere with blood pressure control in new-onset hypertension and treatment-resistant hypertension. American journal of hypertension. 2018; 31(12): 1324-1331.
Wei FF, Zhang ZY, Huang QF, et al. Diagnosis and management of resistant hypertension: state of the art. Nature Reviews Nephrology. 2018; 14(7): 428-441.
Ruilope LM, Rodríguez-Sánchez E, Navarro-García JA, et al. Resistant hypertension: new insights and therapeutic perspectives. European Heart Journal-Cardiovascular Pharmacotherapy. 2020; 6(3): 188-193.
Chernova I, Krishnan N. Resistant hypertension updated guidelines. Current Cardiology Reports. 2019; 21(10): 1-10.
Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. American journal of hypertension. 2015; 28(3): 355-361.
Sheth G, Joshi K. Role of spironolactone in patients with resistant hypertension: A narrative review. Heart India. 2021; 9(1): 3-11.
de la Sierra A, Armario P, Oliveras A, et al. Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension. Journal of Hypertension. 2018; 36(7): 1563-1570.
Ábrahám G, Dézsi CA. The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: the results of the PETRA study. Advances in Therapy. 2017; 34(7): 1753-1763.
Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clinical drug investigation. 2014; 34(10): 701-708.
Narita K, Hoshide S, Kario K. Association of treatment-resistant hypertension defined by home blood pressure monitoring with cardiovascular outcome. Hypertension Research. 2022; 45(1): 75-86.
Kario K, Hoshide S, Narita K, et al. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: the JAMP study. Hypertension. 2021; 78(6): 1781-1790.
Kreutz R, Scholze J, Douros A. Single-pill triple fixed dose combination therapy with single component drug monitoring in treatment-resistant hypertension: a pilot study. Current Vascular Pharmacology. 2018; 16(2): 197-203.
